Marc C Chamberlain. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » Angiogenesis Inhibitors/therapeutic useAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Phytogenic/therapeutic useAntineoplastic Combined Chemotherapy Protocols/therapeutic useBevacizumabBrain Neoplasms/drug therapyBrain Neoplasms/geneticsBrain Neoplasms/pathologyCamptothecin/analogs & derivativesCamptothecin/therapeutic useChromosomes, Human, Pair 1/geneticsGenetic Predisposition to Disease/geneticsGenotypeHumansIrinotecanMutation/geneticsNeoplasm Recurrence, Local/drug therapyNeoplasm Recurrence, Local/physiopathologyNeoplasm Recurrence, Local/prevention & controlOligodendroglioma/drug therapyOligodendroglioma/geneticsOligodendroglioma/pathologySurvival RateTreatment Outcome
Substances： See more » Angiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, PhytogenicBevacizumabIrinotecanCamptothecin
Year: 2010 PMID： 20065257 DOI： 10.1212/WNL.0b013e3181c775e3
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910